Calls for papers
-
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced… Read more . . .
-
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company’s PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the… Read more . . .
-
According to Lupin, Health Canada has approved the company’s generic version of Boehringer Ingelheim’s Spiriva tiotropium bromide inhalation powder for the treatment of COPD. In the UK, the MHRA approved the company’s Lutio tiotropium DPI… Read more . . .
-
Altamira Therapeutics announced that the NASAR trial comparing its Bentrio bentonite-based gel nasal spray to saline nasal spray in patients with seasonal allergic rhinitis met its primary endpoint, demonstrating a statistically significant reduction in nasal… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced the appointment of former Acorda Therapeutics Head of R&D and Chief Medical Officer Burkhard Blank as MannKind’s new Executive VP, Research & Development, and Chief Medical Officer. At Acorda, he… Read more . . .
-
Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company’s AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH)… Read more . . .
-
Inhaler testing equipment maker Copley Scientific has announced the appointment of Clair Brooks as Applications Specialist “to maintain a customer-centric focus as growth continues.” Brooks was most recently a field application specialist at Primerdesign, a… Read more . . .
-
Ceapro has presented results from a pre-clinical study of inhalable yeast beta glucans processed with the company’s pressurized gas expanded (PGX) technology at ATS, the company said. The study, which was conducted in collaboration with McMaster… Read more . . .
-
Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray
Bristol University spinout Halo Therapeutics announced that it has raised £1.5 million in a funding round led by the Development Bank of Wales to support a Phase 1 trial of the company’s HTLX-1 linoleic acid… Read more . . .
-
The FDA has approved Indivior’s Opvee nalmefene nasal spray (OPNT003) for the treatment of opioid overdose, the company announced. Indivior recently acquired the intranasal nalmefene product as part of its acquisition of Opiant Pharmaceuticals. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland